Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure
- PMID: 18677966
- DOI: 10.1055/s-0031-1296504
Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure
Abstract
Drug resistance is the major reason for failure in cancer chemotherapy. Resistance may be either pre-existent (intrinsic resistance), or induced by drugs (acquired resistance), So far, no strategy has been found to overcome resistance, which is based on highly complex and individually variable biological mechanisms. In present clinical practice, drug resistance can only be recognized during treatment, after long lag times. Thus diagnostic tests are re quired, indicating resistance at an earlier stage, in order to avoid unnecessary medication, frequently associated with toxic side-effects. A number of new anti-cancer drugs are now available. In contrast to the unspecifically acting cytostatic chemotherapy, these compounds have targeted actions. However, as recent studies have shown, resistances and severe side-effects can also be found with targeted drugs. With the increasing number of new treatment regimens, the early diagnosis of resistance will optimize therapy, and indeed will be indispensable for individual cancer therapy. The resistance assays available for use in clinical practice should be integrated into cancer therapy. Research into this neglected area needs to be intensified.
Similar articles
-
Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy?Pharmacology. 2008;81(3):196-203. doi: 10.1159/000112864. Epub 2008 Jan 7. Pharmacology. 2008. PMID: 18176090 Review.
-
Molecular mechanisms of drug resistance.J Pathol. 2005 Jan;205(2):275-92. doi: 10.1002/path.1706. J Pathol. 2005. PMID: 15641020 Review.
-
Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.Drug Resist Updat. 2011 Jun;14(3):150-63. doi: 10.1016/j.drup.2011.01.003. Epub 2011 Feb 16. Drug Resist Updat. 2011. PMID: 21330184 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
[Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].Yao Xue Xue Bao. 2009 Apr;44(4):333-7. Yao Xue Xue Bao. 2009. PMID: 19545047 Review. Chinese.
Cited by
-
Molecular mechanisms associated with chemoresistance in esophageal cancer.Cell Mol Life Sci. 2022 Feb 3;79(2):116. doi: 10.1007/s00018-022-04131-6. Cell Mol Life Sci. 2022. PMID: 35113247 Free PMC article. Review.
-
CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.Cell Mol Biol Lett. 2022 Jun 17;27(1):49. doi: 10.1186/s11658-022-00348-2. Cell Mol Biol Lett. 2022. PMID: 35715750 Free PMC article. Review.
-
Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.Br J Clin Pharmacol. 2016 Nov;82(5):1180-1188. doi: 10.1111/bcp.12844. Epub 2015 Dec 26. Br J Clin Pharmacol. 2016. PMID: 26609914 Free PMC article. Review.
-
Anticancer Effects of Abietane Diterpene 7α-Acetoxy-6β-hydroxyroyleanone from Plectranthus grandidentatus and Its Semi-Synthetic Analogs: An In Silico Computational Approach.Molecules. 2024 Apr 16;29(8):1807. doi: 10.3390/molecules29081807. Molecules. 2024. PMID: 38675627 Free PMC article.
-
Genetic and microenvironmental evolution of colorectal liver metastases under chemotherapy.Cell Rep Med. 2024 Dec 17;5(12):101838. doi: 10.1016/j.xcrm.2024.101838. Epub 2024 Dec 3. Cell Rep Med. 2024. PMID: 39631402 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources